SCHEMBL6726671

SCHEMBL6726671

CN(C)CCOc1ccc2[nH]cc(C(=O)Nc3ccccn3)c2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.43
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
TP53 P04637 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
GRM5 P41594 2/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
FGFR3 P22607 1/20 0.41
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTR1A P08908 1/20 0.40
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
HTR1F P30939 1/20 0.40
SGMS2 Q8NHU3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6726254 0.95 NPC1 (0.42) PIM1NPC1RAB9AMEN1KMT2A
SCHEMBL6726955 0.94 NPC1 (0.41) PIM1NPC1RAB9AMEN1KMT2A
SCHEMBL6727000 0.91 RXFP1 (0.44) PIM1NPC1RAB9AMEN1KMT2A
SCHEMBL6734017 0.89 RXFP1 (0.43) PIM1NPC1RAB9AMEN1KMT2A
SCHEMBL6721906 0.88 RXFP1 (0.42) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL6722139 0.87 RXFP1 (0.54) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL6722035 0.86 HTR2C (0.44) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL6724826 0.86 NPC1 (0.40) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL6722073 0.85 NPC1 (0.42) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL6728799 0.85 NPC1 (0.41) NPC1RAB9AMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673811-B1 TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS NEUROGEN CORPORATION 2004-01-06 US claimed
US-6673811-B1 TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS NEUROGEN CORPORATION 2004-01-06 US disclosed